Menu
Federal Contractor Misconduct Database (FCMD)
The federal government routinely awards contracts to companies with
histories of misconduct, including
…
contract fraud and other
violations. POGO believes that providing this website will help to
improve contracting decisions and increase public knowledge of how
the government spends billions of taxpayer dollars each year.
Read more…
Illegally Restricting the U.K. Seroxat Market
The U.K. Competition and Markets Authority (CMA) fined GlaxoSmithKline £37.6 million (US$53.7 million) for illegally preventing competitors from developing a generic replacement for Glaxo’s anti-depressant drug Seroxat (paroxetine). The fines cover the period 2001 to 2004, when Generics UK and Alpharma, who were seeking to enter the UK market with rival products, agreed to a “pay-for-delay” scheme with Glaxo by which the companies were paid over £50 million by Glaxo in exchange for withholding their products from the market.
- Misconduct Type
- Antitrust
- Enforcement Agency
- International
- Contracting Party
- None
- Court Type
- Administrative
- Disposition
- Fine
- Date of Fine Announcement
- 2/12/2016
